Malignant Mesothelioma - Pipeline Insight, 2024

Malignant Mesothelioma - Pipeline Insight, 2024

DelveInsight’s, “Malignant Mesothelioma - Pipeline Insight, 2024,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Malignant Mesothelioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Malignant Mesothelioma Understanding

Malignant Mesothelioma: Overview

Malignant mesothelioma is a rare growth of mesothelial cells strongly associated with asbestos exposure. Mesothelial cells form the lining layers of the viscera. Mesothelioma can occur at any mesothelial layer such as the peritoneum or pericardium. The pleural layer is by far the most commonly affected, giving rise to malignant pleural mesothelioma. The risk of developing mesothelioma was described as 10% over the lifetime of an asbestos worker, with up to 70% of all mesothelioma cases involving documented asbestos exposure. Signs and symptoms associated with mesothelioma are relatively nonspecific and can be seen with almost any intrathoracic disease process, benign or malignant. Most patients have a cough, usually nonproductive. Dyspnea is also common. Chest wall pain may be a relatively unique symptom, usually described as a focal ache. There may be palpable soft tissue fullness or mass and decreased respiratory sounds with dullness to percussion due to an underlying pleural effusion. Some patients develop splinting and even scoliosis toward the ipsilateral side.

""Malignant Mesothelioma - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Malignant Mesothelioma pipeline landscape is provided which includes the disease overview and Malignant Mesothelioma treatment guidelines. The assessment part of the report embraces, in depth Malignant Mesothelioma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence in Malignant Mesothelioma R&D. The therapies under development are focused on novel approaches to treat/improve in Malignant Mesothelioma.
• In April 2022, Ascentage Pharma announced that the combination of palbociclib and APG-2449 synergistically inhibits tumor growth in mesothelioma and such effect is mediated by induced autophagy and enhanced cellular senescence. The preclinical study suggests that APG-2449 combined with CDK4/6 inhibitors may have therapeutic potential in mesothelioma and may warrant future clinical development.
• In July 2021, The FDA granted an orphan drug designation to the anticancer drug paclitaxel-hyaluronic acid (Oncofid-P) for the treatment of malignant mesothelioma, according to a press release by Fida Farmaceutici.

This segment of the Malignant Mesothelioma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Malignant Mesothelioma Emerging Drugs

• INCB001158: Incyte Corporation

INCB001158 (CB-1158) is an investigational first-in-class, novel small molecule arginase inhibitor. Arginase is an enzyme that suppresses the immune-mediated destruction of tumors by depleting levels of a key amino acid, L-arginine, from the tumor microenvironment. A number of cell types in the tumor microenvironment, including myeloid-derived suppressor cells, macrophages, and neutrophils, can secrete arginase. L-arginine deprivation can act via nutrient sensor pathways to exert several suppressive effects on T-cell function, inhibiting proliferation, decreasing cytokine production, and diminishing expression of the T-cell receptor CD3ζ chain. Arginase activity may thus impair T-cell mediated anti-tumor responses

• RSO-021: RS Oncology

RSO-021 is a novel irreversible inhibitor of a key mitochondrial enzyme PRX3 (upregulated in cancer cells) regulating oxidative stress pathways. Treatment with RSO-021 will be administered weekly via an intrapleural catheter after routine pleural effusion drainage.

• Pegargiminase: Polaris Pharmaceuticals

Pegargiminase (ADI-PEG 20) is a potential first-in-class targeted cancer therapy in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma (HCC) and malignant pleural mesothelioma (MPM). Pegargiminase is well tolerated, both as a monotherapy and as part of a combination therapy.

Further product details are provided in the report……..

Malignant Mesothelioma: Therapeutic Assessment

This segment of the report provides insights about the different Malignant Mesothelioma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Malignant Mesothelioma

There are approx. 20+ key companies which are developing the therapies for Malignant Mesothelioma. The companies which have their Malignant Mesothelioma drug candidates in the most advanced stage, i.e. Phase III include, Polaris Pharmaceuticals.

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Malignant Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Intramuscular
• Oral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small Molecule
• Gene Therapy
• Stem Cell Therapy
• Antidepressants
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Malignant Mesothelioma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Malignant Mesothelioma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Malignant Mesothelioma drugs.

Malignant Mesothelioma Report Insights

• Malignant Mesothelioma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Malignant Mesothelioma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Malignant Mesothelioma drugs?
• How many Malignant Mesothelioma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Malignant Mesothelioma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Malignant Mesothelioma?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Malignant Mesothelioma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Epizyme
• Ys Therapeutics
• Novartis
• Bayer
• RS Oncology
• Polaris Pharmaceuticals
• Merck
• Vivace Therapeutics
• Shionogi
• Mirati Therapeutics
• Incyte Corporation
• TCR2 Therapeutics
• SOTIO Biotech
• Pfizer
• Ascentage Pharma
• Fida Farmaceutici

Key Products

• Tazemetostat
• YS110
• IAG933
• BAY94 9343
• RSO-021
• Pegargiminase
• Niraparib
• VT 3989
• S-488210
• MRTX 1719
• INCB001158
• Gavocabtagene autoleucel
• TBio-6517
• SO-C101
• PF-06952229
• APG-2449
• Oncofid-P